Next Article in Journal
Laparoscopic Fluorescence Guided Detection of Uterine Niche—The Next Step in Surgical Diagnosis and Treatment
Next Article in Special Issue
Thickness of Biceps and Quadriceps Femoris Muscle Measured Using Point-of-Care Ultrasound as a Representation of Total Skeletal Muscle Mass
Previous Article in Journal
Are Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 Useful as Markers in Diagnostic Management of Children with Newly Diagnosed Ulcerative Colitis?
Previous Article in Special Issue
ADAMTS13, VWF, and Endotoxin Are Interrelated and Associated with the Severity of Liver Cirrhosis via Hypercoagulability
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 11
Issue 9
10.3390/jcm11092656
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Sarcopenia and Myosteatosis Are Associated with Neutrophil to Lymphocyte Ratio but Not Glasgow Prognostic Score in Colorectal Cancer Patients

by
Raila Aro
1,2,*,
Sanna Meriläinen
1,2,
Päivi Sirniö
3,4,
Juha P. Väyrynen
3,4,
Vesa-Matti Pohjanen
3,4,
Karl-Heinz Herzig
4,5,6,
Tero T. Rautio
1,2,
Elisa Mäkäräinen
1,2,
Reetta Häivälä
1,2,
Kai Klintrup
1,2,
Markus J. Mäkinen
3,4,
Juha Saarnio
1,2 and
Anne Tuomisto
3,4,*
1
Department of Surgery, Oulu University Hospital, 90014 Oulu, Finland
2
Division of Operative Care, Medical Research Center, Oulu University Hospital, University of Oulu, 90014 Oulu, Finland
3
Cancer and Translational Medicine Research Unit, University of Oulu, P.O. Box 5000, 90014 Oulu, Finland
4
Oulu University Hospital, Medical Research Center Oulu, P.O. Box 21, 90029 Oulu, Finland
5
Research Unit of Biomedicine, Department of Physiology, University of Oulu, P.O. Box 5000, 90014 Oulu, Finland
6
Department of Pediatric Gastroenterology and Metabolism, Poznan University of Medical Sciences, 61-701 Poznan, Poland
*
Authors to whom correspondence should be addressed.
J. Clin. Med. 2022, 11(9), 2656; https://0-doi-org.brum.beds.ac.uk/10.3390/jcm11092656
Submission received: 1 March 2022 / Revised: 29 April 2022 / Accepted: 5 May 2022 / Published: 9 May 2022
(This article belongs to the Special Issue Sarcopenia and Gastrointestinal Disease)
Browse Figures
Review Reports Versions Notes

Abstract

:
Cancer patients commonly present sarcopenia, myosteatosis, and systemic inflammation, which are risk factors of poor survival. In this study, sarcopenia and myosteatosis were defined from preoperative body computed tomography scans of 222 colorectal cancer (CRC) patients and analyzed in relation to tumor and patient characteristics, markers of systemic inflammation (modified Glasgow prognostic score (mGPS), neutrophil–lymphocyte ratio (NLR), serum levels of C-reactive protein (CRP), albumin, and 13 cytokines, and survival. Of the systemic inflammation markers, sarcopenia and/or myosteatosis associated with elevated NLR (p = 0.005) and low albumin levels (≤35 g/L) (p = 0.018), but not with mGPS or serum cytokine levels. In addition, myosteatosis was associated with a proximal tumor location (p = 0.039), serrated tumor subtype (p < 0.001), and severe comorbidities (p = 0.004). Multivariable analyses revealed that severe comorbidities and serrated histology were independent predictors of myosteatosis, and older age and elevated NLR were independent indicators of sarcopenia. Myosteatosis associated with shorter overall survival in univariable analysis (HR 1.959, 95% CI 1.24–3.10, p = 0.004) but not in multivariable analysis (p = 0.075). We conclude that sarcopenia and myosteatosis were associated with inflammatory marker NLR, but not with mGPS. Moreover, patients with serrated CRC may have an increased risk of myosteatosis. Myosteatosis or sarcopenia were not independent predictors of patient survival.

1. Introduction

Sarcopenia and myostetosis are common manifestation of frailty, and they are associated with old age and several chronic devastating illnesses, including cancer. In colorectal carcinoma patients, sarcopenia and myosteatosis precede and culminate in cancer cachexia [1,2,3,4], which is a syndrome defined by the loss of muscle mass with or without reduction in fat mass [5,6]. Sarcopenia is characterized by loss of muscle strength, function, and mass, whereas myosteatosis is defined as increased fat infiltration in muscle. Sarcopenia has been associated with older age, nutritional deficiencies, cancer, and heart and renal failure, potentially reflecting decreasing physical activity, metabolic disturbance, inflammation, and abnormal hormonal and cytokine levels [7,8,9]. Myosteatosis has been linked with aging, insulin resistance, glucocorticoid stimulation, altered leptin signaling, estrogen and androgen deficiency, and physical inactivity [10]. Sarcopenia and myosteatosis have been reported to represent risk factors for poor survival and postoperative complications in colorectal cancer (CRC) [1,11,12,13,14].
Systemic inflammation is a condition characterized by increased production of proinflammatory cytokines and acute phase proteins [15]. Systemic inflammation can be observed in 21–41% of CRC patients before surgery, most commonly in patients with an advanced disease [16,17,18]. Importantly, systemic inflammation is an independent poor prognostic factor in CRC and in other malignancies [17,18]. Frequently used biomarkers of systemic inflammation include circulating C-reactive protein (CRP) levels [19], modified Glasgow prognostic score (mGPS), a measure based on elevated serum CRP level and decreased serum albumin level [15,17,20], and blood neutrophil/lymphocyte ratio NLR [21].
In CRC, systemic inflammation has been reported to be associated with sarcopenia and myosteatosis [22,23,24], but associations with more detailed serum biomarker networks have not been conducted [25]. In this study, we aimed to investigate the relationships of sarcopenia and myosteatosis with several important circulating inflammatory mediators. Furthermore, we assessed the prognostic significance of sarcopenia and myosteatosis.

2. Materials and Methods

2.1. Data Collection

This retrospective study is based on a cohort of 378 colorectal cancer patients operated on in Oulu University Hospital during 2006–2014 who had signed written informed consent for study participation [16,26]. Patients were selected for the study if (a) preoperative venous-phase tomography was performed; (b) serum samples were taken; (c) no preoperative chemotherapy or chemoradiotherapy was given; and (d) no synchronous malignancy was observed. After application of these exclusion criteria, 222 patients were eligible.
Patient data were collected from patient registries at Oulu University Hospital, including age, comorbidities, medication, gender, tumor location, 90-day and 5-year postoperative mortality, the American Society of Anesthesiologists (ASA) class, and date of cancer recurrence. Data were collected until the patients’ death or until the end of observation period (12/2019) when the 5-year follow-up was reached for all patients. Preoperative laboratory markers including blood leucocyte differential count, CRP, hemoglobin, albumin, and carcinoembryonic antigen (CEA) were measured [16,27]. As previously described, mGPS was derived from CRP and albumin levels [20]. NLR was calculated, and NLR > 3 was regarded as high [28]. Tumor data were recorded by re-evaluation of histologic sections, including TNM8 classification, WHO2010 grading, and serrated morphology. The features favoring serrated CRC included epithelial serrations, clear or eosinophilic cytoplasm, abundant cytoplasm, vesicular nuclei, distinct nucleoli, intracellular and extracellular mucin production, and absence or scarceness of necrosis [29,30]. BRAF V600E mutation was detected by mutation-specific VE1 immunohistochemistry [31]. Serum cytokine levels were analyzed using a multiplex assay in patients operated on between April 2006 and January 2010 [16,26]. A total of 13 cytokines (IL-1R1, IL-4, IL-6, IL-7, CXCL8, IL-9, IL-12p70, IFNG, CXCL10, CCL2, CCL4, CCL11, and PDGF-BB) with less than three values (1.5%) outside the assay working range were included in this study.

2.2. Body Composition Measurements

Skeletal muscle areas were measured in the preoperative venous-phase using computed tomography (CT) examinations. A single image in which both transverse processes were visible at the level of third lumbar vertebra was selected from CT pictures. The total cross-sectional muscle area (CSMA) of abdominal (transverse, external oblique, internal oblique, and rectus abdominis) and back muscles (psoas and paraspinal muscles) in the L3 level were measured by using the range −29 to +150 Hounsfield units (HU). CSMA was normalized for patient stature and designated as skeletal muscle index. The SMI was calculated as CSMA/height2 [32] and BMI using the formula weight (kg)/height2 (m2). Sarcopenia was defined as SMI < 41 cm2/m2 for women and 43 cm2/m2 for men with BMI < 25 kg/m2 and 53 cm2/m2 for men with BMI ≥ 25 kg/m2 [32]. Muscle density was measured as mean HU at this cross-sectional muscle area. Myosteatosis was defined as HU < 41 for patients with BMI < 25 kg/m2 and HU < 33 for patients with BMI ≥ 25 kg/m2 [32].

2.3. Statistical Analysis

All analyses were performed using SPSS for Windows (IBM Corp. Released 2018. IBM SPSS Statistics for Windows, Version 27.0. Armonk, NY, USA: IBM Corp.). Pearson’s χ2-test or Fisher’s exact test were used for the comparison of the categorical variables. The statistical significances of the associations between categorical and continuous variables were analyzed using the Mann–Whitney test (comparing two classes) or Kruskal–Wallis test (comparing three or more classes). Multivariable binary logistic regression models of the associations of sarcopenia/myosteatosis with systemic inflammatory markers and selected clinicopathological factors using enter method were conducted. Survival curves were plotted according to the Kaplan–Meier method. Backward conditional stepwise Cox regression was used for multivariable survival modeling. Statistically significant variables from univariable analyses were considered for inclusion in multivariable analyses. Two-tailed values were considered statistically significant at p < 0.05.

3. Results

3.1. Patients Characteristics

We analyzed sarcopenia and myosteatosis in 222 CRC patients. The characteristics of all patients are presented in Table 1. The majority of patients were 70 or older (57%), male (53%), overweight or obese (66%), had conventional CRC (70%), and had undergone an operation with curative intent (87%). Cancer recurrence at the 5-year follow-up was diagnosed in 40 (18%) patients, and 147 (66%) patients were alive 5 years after the operation. The prevalence of sarcopenia in this cohort was 55% and the prevalence of myosteatosis was 30%. Sarcopenia and myosteatosis coexisted in 47 (21%) patients, 76 (34%) patients had sarcopenia alone, and 20 (9%) had myosteatosis alone (Figure 1a). Sarcopenia was prevalent in 47 (70%) patients with myosteatosis, whereas only 38% of patients with sarcopenia were also affected by myosteatosis. A total of 45 (20%) patients had mGPS > 0 and 55 (25%) patients had NLR > 3, but only 17 (7.7%) patients presented concurrent NLR > 3 and mGPS > 0 (Figure 1b). Hence, although both mGPS and NLR are markers of systemic inflammation, in only a few patients was systemic inflammation detected by both of these markers, and in most patients, systemic inflammation could only be detected with one of these two markers. Therefore, mGPS and NLR do not entirely mirror the same tumor–host interactions in CRC patients.

3.2. Sarcopenia and Myosteatosis in Relation to Clinicopathological Characteristics

The relationships between sarcopenia and myosteatosis and the clinicopathological variables are presented in Table 2. Sarcopenia, myosteatosis, and their combined presence associated with older age (p < 0.001) and higher ASA score (p = 0.004). Sarcopenia and concurrent sarcopenia and myosteatosis were associated with lower BMI (p < 0.001). Myosteatosis was associated with proximal tumor location (p = 0.039), serrated morphology (p < 0.001), and blood pressure lowering medication (p = 0.043).

3.3. Sarcopenia and Myosteatosis in Relation to Systemic Inflammatory Markers

As our main analysis, we analyzed the relationships of sarcopenia and myosteatosis with systemic inflammatory markers. First, we evaluated the correlations between two-tiered sarcopenia and myosteatosis and systemic inflammatory markers (Supplementary Table S1 and Figure 2). Sarcopenia showed a trend of a negative association with serum Hb level, and myosteatosis negatively associated with IL9, had a trend of negative association with INFg, and a trend of positive association with NLR. With the four-tiered sarcopenia–myosteatosis combination variable, NLR was elevated both in sarcopenic and myosteatotic patients, most frequently in patients with concurrent sarcopenia and myosteatosis (Table 2, p = 0.005). Muscle abnormalities neither associated with mGPS classification (p = 0.331) nor elevated CRP level (CRP ≤ 10 vs. CRP > 10, p = 0.584), but all patients with hypoalbuminemia (<35 g/L) had either sarcopenia or myosteatosis or both (p = 0.018). In addition, myosteatosis was associated with anemia (Table 3, p = 0.011). Comparison of serum cytokine and chemokine levels and blood cell counts in relation to sarcopenia and myosteatosis is presented in Table 3. Serum cytokine concentrations were not significantly associated with sarcopenia or myosteatosis.

3.4. Multivariable Analyses

The multivariable analyses showed that myosteatosis was independently associated with serrated histology (multivariable OR 3.76, 95% CI 1.82–7.76, p < 0.001) and higher ASA score (multivariable OR 2.66, 95% CI 1.20–5.93, p = 0.017, Table 4) and sarcopenia with age (multivariable HR 3.23, 95% CI 1.65–6.31, p < 0.001) and elevated NLR (multivariable HR 2.34, 95% CI 1.13–8.84, p = 0.022, Table 5).

3.5. Survival Analyses

In univariable analyses based on separate, two-tiered sarcopenia and myosteatosis variables (Figure 3 and Supplementary Figure S1), Kaplan–Meier curves demonstrated that sarcopenia was not statistically significantly associated with disease-free survival (DFS) (p = 0.102), cancer-specific survival (CSS) (p = 0.643), or overall survival (p = 0.289). Myosteatosis was associated with shorter OS (multivariable HR 1.959, 95% CI 1.24–3.10, p = 0.004, Figure 3A) but not with DFS (p = 0.704) or CSS (p = 0.106). In the multivariable Cox proportional hazard regression model, adjusted for tumor stage and age, myosteatosis showed a tendency toward an association with worse OS (Table 6, p = 0.075).
In analyses based on the four-tiered sarcopenia–myosteatosis combination variable, Kaplan–Meier curves (Figure 3) visualized that presence of sarcopenia alone was associated with shorter DFS (p = 0.010), but the patients with myosteatosis alone (p = 0.088) or both sarcopenia and myosteatosis (p = 0.703) had similar DFS as the patients without the muscle abnormalities. Patients with myosteatosis alone had the worse CSS (p = 0.002) and OS (p = 0.002) than patients without muscle abnormalities (Figure 3). Additionally, the patients with both myosteatosis and sarcopenia had worse OS than patients without muscle abnormalities (p = 0.012). In multivariable Cox analysis with the four-tiered sarcopenia–myosteatosis variable adjusted for tumor stage and age, presence of sarcopenia alone, myosteatosis alone, or both sarcopenia and myosteatosis were not statistically significantly associated with CSS and OS (Supplementary Table S2). However, presence of sarcopenia alone (p = 0.029) and presence of myosteatosis alone (p = 0.011) also associated with worse DFS in multivariable analysis.

3.6. Sarcopenia and Myosteatosis in Stage I–III CRC

Since cancer metastasis is associated with systemic inflammation [21], we conducted subgroup analyses of the association of sarcopenia and myosteatosis with clinicopathological characteristics (Supplementary Table S3), and with cytokines, chemokines, and blood cell counts (Supplementary Table S4) in stage I–III CRC patients.
In this analysis, similar to stage I–IV CRCs, sarcopenia, myosteatosis, and their coexistence associated with older age (p < 0.001), higher ASA score (p < 0.001), and use of blood pressure lowering medication (p = 0.023). Sarcopenia and concurrent sarcopenia and myosteatosis were associated with lower BMI (p < 0.001) and elevated NLR (p = 0.006). Myosteatosis and concurrent myosteatosis and sarcopenia were associated with proximal tumor location (p = 0.021), serrated morphology (p = 0.002), and lower albumin level (≤35 g/L). However, when metastatic CRC patients were excluded, BRAF mutation also associated with myosteatosis alone or together with sarcopenia (p = 0.045). Serum cytokine concentrations were not significantly associated with sarcopenia or myosteatosis. Only lower IL-9 level associated with presence of myosteatosis, sarcopenia, or both muscle abnormalities (p = 0.037). Multivariable regression models found the same factors associating with sarcopenia and myosteatosis in stage I–III patients as in stage I–IV patients: Myosteatosis associated with serrated histology (multivariable OR 3.54, 95% CI 1.56–8.00, p = 0.002) and higher ASA score (multivariable OR 4.42, 95% CI 1.70–11.47, p = 0.002, Supplementary Table S5) and sarcopenia with age (multivariable HR 3.92, 95% CI 1.87–8.23, p < 0.001) and elevated NLR (multivariable HR 3.17, 95% CI 1.38–7.28, p = 0.007, Supplementary Table S6).
In survival analyses of stage 1–3 patients, sarcopenia did not associate with OS, CSS, or DFS, and myosteatosis associated only with shorter OS (p = 0.021), not with CSS or DFS (Supplementary Figure S2). However, in stage I–III patients, myosteatosis also significantly associated with poor OS in the multivariable Cox proportional hazard regression model adjusted for tumor stage and age, (multivariable HR 1.81, 95% CI 1.00–3.26, p = 0.048, Supplementary Table S7).

4. Discussion

We evaluated the associations between muscle density abnormalities, systemic inflammation, and patient characteristics. We found that 55% of CRC patients were affected by sarcopenia and 30% by myosteatosis. Preoperative sarcopenia and myosteatosis associated with advanced age, lower BMI, and elevated NLR, but not with mGPS classification. Moreover, myosteatosis associated with higher ASA grade, proximal location, and serrated morphology.
Previous studies have reported a wide prevalence range of both sarcopenia (12–60%) [2,3,11,23,33,34,35,36] and myosteatosis (30–78%) [2,3,33,37] in CRC patients. A reason for this variation may be patients’ ethnicity, sex, and different skeletal muscle cutoff points. The sarcopenia and myosteatosis prevalence in our cohort are comparable to these previous studies. In our study, in 21% of the CRC patients, sarcopenia and myosteatosis occurred concurrently. To our knowledge, the effects of concurrent presence of sarcopenia and myosteatosis in CRC have only been reported in one publication [33], in which the prevalence of concurrent presence of sarcopenia and myosteatosis was similar to our study (around 20%).
Systemic inflammation is regarded as an important factor driving cachexia-related symptoms [5], and recent meta-analysis of 11,474 CRC patients indicated a consistent association between sarcopenia and systemic inflammation [38]. However, in our cohort, sarcopenia, myosteatosis, or presence of both were not significantly associated with an elevated mGPS. Dolan et al. [22] found an increased incidence of both sarcopenia and myosteatosis with mGPS 2 class, which was defined by elevated CRP levels and decreased albumin levels. In our cohort, only 4 (1.8%) patients were classified as mGPS 2, whereas in the study by Dolan et al. [22] 13.5% of the patients were classified as mGPS 2, and in a study by McMillan et al. [20], 12% of patients were mGPS 2. In our study, hypoalbuminemia was detected only in 13 (5.9%) CRC patients, and both sarcopenia and myosteatosis associated with decreased albumin levels (p = 0.029 and p = 0.003). In many other studies, the reported prevalence of hypoalbuminemia in patients with operable CRC has been higher, 22–30% [4,39]. Hence, the low hypoalbuminemia prevalence in our cohort may account for the lack of association between muscle abnormalities and mGPS in our study. In our cohort, systemic inflammation was present in 20% of CRC patients when evaluated by the mGPS classification and in 24.8% when defined by NLR. Dolan et al. [22] found a similar proportion of systemically inflamed patients with 23% of the CRC patients based on mGPS classification and 40% of CRC patients based on increased NLR.
Both mGPS and elevated NLR are regarded as markers of systemic inflammation [17,40]. Although there was an association between NLR and mGPS (p = 0.016, data not shown), only 31% of patients with raised NLR also had elevated mGPS, and the majority of patients with increased NLR had normal CRP and albumin levels (Figure 1b). Thus, increased NLR and elevated mGPS score may have both common and unrelated causes. CRP and albumin, the measured variables in mGPS classification, are acute phase proteins reflecting elevated circulating IL6 levels [41]. NLR is elevated as a response to inflammation, but also in response to metabolic alterations such as hyperglycemia [42] and insulin resistance [43,44]. Concordant with the lack of association between muscle abnormalities and mGPS classification, serum cytokine levels were not significantly associated with muscle abnormalities, either (Table 3).
In our study, sarcopenic and myosteatotic patients were more often over 70 years. In the literature, 4.6–36.5% of people at an average age of 70 were sarcopenic [45]. Age is a well-known risk factor for sarcopenia, and in our cohort higher age together with elevated NLR were associated with sarcopenia in multivariable analysis, whereas serrated morphology and higher ASA classification associated with myosteatosis. Therefore, sarcopenia and myosteatosis are muscle abnormalities potentially driven by different mechanisms.
Myosteatosis was associated with the serrated histological subtype of CRC (p < 0.001). Serrated CRCs constitute 30% of all CRCs, characteristically developing from serrated precursor lesions. One of the typical molecular features of serrated CRC is the activation of the MAPK-ERK signaling pathway via activating mutations of BRAF or KRAS [46]. In the four-tiered sarcopenia–myosteatosis variable, neither sarcopenia nor myosteatosis were significantly associated with the BRAF mutation, but when evaluated as separate variables, myosteatosis associated with the BRAF mutation (p = 0.024, data not shown). Mutated KRAS alters glucose metabolism leading to the production of ATP and other metabolic intermediates in anaerobic glycolysis, and not by citric acid synthesis [47]. Mutant KRAS also upregulates expression of the GLUT1 glucose transporter, promoting glucose uptake by cells. Interestingly, several studies have demonstrated higher glucose accumulation in 18F-FDG PET/CT scans in CRCs with KRAS/NRAS/BRAF mutations [48]. The association between myosteatosis and serrated morphology suggests that serrated CRC patients might have an increased risk of myosteatosis, and we hypothesize that this may reflect higher glucose metabolism in serrated CRC.
Myosteatosis was associated with proximal tumor location in our cohort and also in other studies [49]. However, multivariable analysis revealed that only serrated histology, not proximal location, was independently associated with myosteatosis. Serrated CRCs are most often localized in proximal colon [50] suggesting that the serrated morphology may be a stronger determinant of myosteatosis than proximal tumor location.
Several studies have indicated the association between sarcopenia and myosteatosis and DFS, CSS, and OS [22,32,51,52,53,54], but also some have not [3,12]. In our cohort, myosteatosis or sarcopenia alone or concurrent sarcopenia and myosteatosis were not associated with survival, although myosteatosis showed a tendency toward an association with worse OS. When the CRC patients with distant metastases were excluded, myosteatosis independently associated with OS. In some of the previous studies [22,32,53], sample size has been larger than in our cohort, which might influence our negative result. In particular, it is not clear why the patients with concurrent sarcopenia and myosteatosis appeared to have similar DFS as those with neither muscle abnormality. Sarcopenia and myosteatosis are multifactorial muscle abnormalities, also associated with sex/race/ethnicity. The studies by Nakanishi et al. [12] and Miyamoto et al. [54] included patients of different ethnicities and cutoff values for muscle abnormalities, which complicates comparison of results.
In addition to the relatively small sample size, some other limitations should be acknowledged. The definition of sarcopenia was limited to myopenia without measuring muscle strength, as such data were not available for this cohort. Multiple factors may contribute to myosteatosis and sarcopenia, such as the patient’s lifestyle and diet, nutritional care before and after surgery, and other environmental exposures, in addition to effects of the tumor and inflammation. While we extensively characterized tumors and systemic inflammatory markers, we did not collect diet or lifestyle data, potentially resulting in residual confounding. Muscle density and circulating biomarker data were based on single preoperative measurements, and follow-up of their development was lacking. Our analysis was retrospective, and further larger prospective studies are required to validate the findings. The strength of our study was the measurement of multiple inflammatory biomarkers, enabling more granular analyses than single biomarker measurements. As the correlations between serum cytokine concentrations and sarcopenia or myosteatosis were generally quite weak, further studies are required to evaluate the molecular mechanisms underlying sarcopenia and myosteatosis.

5. Conclusions

In conclusion, sarcopenia and myosteatosis were associated with elevated NLR but not with the mGPS score of systemic inflammation. Myosteatosis was also associated with the serrated CRC subtype, suggesting that patients with serrated CRC might be at higher risk of myosteatosis.

Supplementary Materials

The following are available online at https://0-www-mdpi-com.brum.beds.ac.uk/article/10.3390/jcm11092656/s1. Table S1: Relationships between two-tiered sarcopenia and myosteatosis and systemic inflammatory markers. Table S2: Relationships between the combined sarcopenia-myosteatosis variable and survival. Table S3: Distribution of clinocopathological factors in myosteatosis and sarcopenia patient groups in stage I-III colorectal cancer. Table S4: Serum cytokine and chemokine levels, blood cell counts and other laboratory parameters in relation to sarcopenia and myosteatosis in stage I-III colorectal cancer. Table S5. Multivariable regression model for myosteatosis probability in stage I-III colorectal cancer. Table S6: Multivariable regression model for sarcopenia probability in stage I-III colorectal cancer. Table S7: Multivariable Cox regression model for overall survival in stage I-III colorectal cancer. Figure S1: Kaplan-Meier survival curves for (A) sarcopenia and disease-free survival, (B) sarcopenia and cancer-specific survival, (C) sarcopenia and overall survival, (D) myosteatosis and disease-free survival, and (E) myosteatosis and cancer-specific survival. Figure S2. Kaplan-Meier survival curves for stage I-III patients (A) myosteatosis and overall survival, (B) myosteatosis and cancer-specific survival, (C) myosteatosis and disease-free survival, (D) sarcopenia and overall survival, (E) sarcopenia and cancer-specific survival, (F) sarcopenia and disease-free survival, (G) the presence of myosteatosis and sarcopenia and overall survival, (H) the presence of myosteatosis and sarcopenia and cancer-specific survival, (I) the presence of myosteatosis and sarcopenia and disease-free survival.

Author Contributions

Conceptualization, R.A., S.M. and A.T.; methodology, software, validation, formal analysis, R.A., S.M., A.T., P.S. and J.P.V.; investigation, R.A., A.T., S.M. and J.P.V.; funding acquisition and resources, S.M., R.A., J.S., A.T. and M.J.M.; data collection, data curation, R.A., S.M., E.M., R.H., K.K., P.S., J.P.V., V.-M.P. and A.T.; writing—original draft preparation, R.A., S.M. and A.T.; writing—review and editing, R.A., S.M., P.S., J.P.V., K.-H.H., T.T.R., E.M., M.J.M., J.S. and A.T.; visualization R.A. and A.T.; project administration and supervision, R.A., S.M., A.T. and M.J.M.; All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by Thelma Mäkikyrö Foundation, the Emil Aaltonen Foundation, Oulu Medical Society Duodecim, the Suorsa Foundation, Terttu Foundation, Finnish Medical Foundation, and VTR funding for 2021.

Institutional Review Board Statement

The study was accepted by the Ethics Committee of the Oulu University Hospital (42/2005, 122/2009) and performed according to the principles of the Declaration of Helsinki. The study was designed in accordance with the REMARK guidelines [55].

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

Not applicable.

Acknowledgments

We thank Riitta Vuento and Erja Tomperi for their excellent assistance in the preparation of the study material.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Aro, R.; Mäkäräinen-Uhlbäck, E.; Ämmälä, N.; Rautio, T.; Ohtonen, P.; Saarnio, J.; Meriläinen, S. The impact of sarcopenia and myosteatosis on postoperative outcomes and 5-year survival in curatively operated colorectal cancer patients—A retrospective register study. Eur. J. Surg. Oncol. 2020, 46, 1656–1662. [Google Scholar] [CrossRef] [PubMed]
  2. Malietzis, G.; Currie, A.C.; Athanasiou, T.; Johns, N.; Anyamene, N.; Glynne-Jones, R.; Kennedy, R.H.; Fearon, K.C.H.; Jenkins, J.T. Influence of body composition profile on outcomes following colorectal cancer surgery. Br. J. Surg. 2016, 103, 572–580. [Google Scholar] [CrossRef] [PubMed]
  3. Van Vugt, J.L.A.; Coebergh van den Braak, R.R.J.; Lalmahomed, Z.S.; Vrijland, W.W.; Dekker, J.W.T.; Zimmerman, D.D.E.; Vles, W.J.; Coene, P.-P.L.O.; IJzermans, J.N.M. Impact of Low Skeletal Muscle Mass and Density on Short and Long-Term Outcome after Resection of Stage I-III Colorectal Cancer. Eur. J. Surg. Oncol. 2018, 44, 1354–1360. [Google Scholar] [CrossRef]
  4. Almasaudi, A.S.; Dolan, R.D.; Edwards, C.A.; McMillan, D.C. hypoalbuminemia reflects nutritional risk, body composition and systemic inflammation and is independently associated with survival in patients with colorectal cancer. Cancers 2020, 12, 1986. [Google Scholar] [CrossRef] [PubMed]
  5. Cederholm, T.; Barazzoni, R.; Austin, P.; Ballmer, P.; Biolo, G.; Bischoff, S.C.; Compher, C.; Correia, I.; Higashiguchi, T.; Holst, M.; et al. ESPEN guidelines on definitions and terminology of clinical nutrition. Clin. Nutr. 2017, 36, 49–64. [Google Scholar] [CrossRef]
  6. Cederholm, T.; Jensen, G.L.; Correia, M.I.T.D.; Gonzalez, M.C.; Fukushima, R.; Higashiguchi, T.; Baptista, G.; Barazzoni, R.; Blaauw, R.; Coats, A.J.S.; et al. GLIM Criteria for the diagnosis of malnutrition—A consensus report from the Global Clinical Nutrition Community. J. Cachexia Sarcopenia Muscle 2019, 10, 207–217. [Google Scholar] [CrossRef] [Green Version]
  7. Bauer, J.; Morley, J.E.; Schols, A.M.W.J.; Ferrucci, L.; Cruz-Jentoft, A.J.; Dent, E.; Baracos, V.E.; Crawford, J.A.; Doehner, W.; Heymsfield, S.B.; et al. Sarcopenia: A time for action. An SCWD position paper. J. Cachexia Sarcopenia Muscle 2019, 10, 956–961. [Google Scholar] [CrossRef]
  8. Fuggle, N.; Shaw, S.; Dennison, E.; Cooper, C. Sarcopenia. Best Pract. Res. Clin. Rheumatol. 2017, 31, 218–242. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  9. Cruz-Jentoft, A.J.; Romero-Yuste, S.; Chamizo Carmona, E.; Nolla, J.M. Sarcopenia, immune-mediated rheumatic diseases, and nutritional interventions. Aging Clin. Exp. Res. 2021, 33, 2929–2939. [Google Scholar] [CrossRef] [PubMed]
  10. Hamrick, M.W.; McGee-Lawrence, M.E.; Frechette, D.M. Fatty Infiltration of skeletal muscle: Mechanisms and comparisons with bone marrow adiposity. Front. Endocrinol. 2016, 7, 69. [Google Scholar] [CrossRef] [Green Version]
  11. Lieffers, J.R.; Bathe, O.F.; Fassbender, K.; Winget, M.; Baracos, V.E. Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. Br. J. Cancer 2012, 107, 931–936. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Nakanishi, R.; Oki, E.; Sasaki, S.; Hirose, K.; Jogo, T.; Edahiro, K.; Korehisa, S.; Taniguchi, D.; Kudo, K.; Kurashige, J.; et al. Sarcopenia is an independent predictor of complications after colorectal cancer surgery. Surg. Today 2018, 48, 151–157. [Google Scholar] [CrossRef] [PubMed]
  13. Vergara-Fernandez, O.; Trejo-Avila, M.; Salgado-Nesme, N. Sarcopenia in patients with colorectal cancer: A comprehensive review. World J. Clin. Cases 2020, 8, 1188–1202. [Google Scholar] [CrossRef]
  14. Lee, C.M.; Kang, J. Prognostic impact of myosteatosis in patients with colorectal cancer: A systematic review and meta-analysis. J. Cachexia Sarcopenia Muscle 2020, 11, 1270–1282. [Google Scholar] [CrossRef] [PubMed]
  15. Tuomisto, A.E.; Mäkinen, M.J.; Väyrynen, J.P. Systemic inflammation in colorectal cancer: Underlying factors, effects, and prognostic significance. World J. Gastroenterol. 2019, 25, 4383–4404. [Google Scholar] [CrossRef] [PubMed]
  16. Kantola, T.; Klintrup, K.; Väyrynen, J.P.P.; Vornanen, J.; Bloigu, R.; Karhu, T.; Herzig, K.-H.; Näpänkangas, J.; Mäkelä, J.; Karttunen, T.J.J.; et al. Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma. Br. J. Cancer 2012, 107, 1729–1736. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  17. McMillan, D.C. The systemic inflammation-based glasgow prognostic score: A decade of experience in patients with cancer. Cancer Treat. Rev. 2013, 39, 534–540. [Google Scholar] [CrossRef] [PubMed]
  18. Park, J.H.; Watt, D.G.; Roxburgh, C.S.D.; Horgan, P.G.; McMillan, D.C. Colorectal cancer, systemic inflammation, and outcome. Ann. Surg. 2016, 263, 326–336. [Google Scholar] [CrossRef]
  19. McMillan, D.C.; Canna, K.; McArdle, C.S. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br. J. Surg. 2003, 90, 215–219. [Google Scholar] [CrossRef] [PubMed]
  20. McMillan, D.C.; Crozier, J.E.M.; Canna, K.; Angerson, W.J.; McArdle, C.S. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int. J. Colorectal Dis. 2007, 22, 881–886. [Google Scholar] [CrossRef] [PubMed]
  21. Dolan, R.D.; McSorley, S.T.; Horgan, P.G.; Laird, B.; McMillan, D.C. The role of the systemic inflammatory response in predicting outcomes in patients with advanced inoperable cancer: Systematic review and meta -analysis. Crit. Rev. Oncol. Hematol. 2017, 116, 134–146. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Dolan, R.D.; Almasaudi, A.S.; Dieu, L.B.; Horgan, P.G.; McSorley, S.T.; McMillan, D.C. The relationship between computed tomography-derived body composition, systemic inflammatory response, and survival in patients undergoing surgery for colorectal cancer. J. Cachexia Sarcopenia Muscle 2019, 10, 111–122. [Google Scholar] [CrossRef] [PubMed]
  23. McSorley, S.T.; Black, D.H.; Horgan, P.G.; McMillan, D.C. The relationship between tumour stage, systemic inflammation, body composition and survival in patients with colorectal cancer. Clin. Nutr. 2018, 37, 1279–1285. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Malietzis, G.; Johns, N.; Al-Hassi, H.O.; Knight, S.C.; Kennedy, R.H.; Fearon, K.C.H.; Aziz, O.; Jenkins, J.T. Low muscularity and myosteatosis is related to the host systemic inflammatory response in patients undergoing surgery for colorectal cancer. Ann. Surg. 2016, 263, 320–325. [Google Scholar] [CrossRef] [PubMed]
  25. Reisinger, K.W.; Derikx, J.P.M.; van Vugt, J.L.A.; Von Meyenfeldt, M.F.; Hulsewé, K.W.; Olde Damink, S.W.M.; Stoot, J.H.M.B.; Poeze, M. Sarcopenia is associated with an increased inflammatory response to surgery in colorectal cancer. Clin. Nutr. 2016, 35, 924–927. [Google Scholar] [CrossRef] [PubMed]
  26. Väyrynen, J.P.; Tuomisto, A.; Väyrynen, S.A.; Klintrup, K.; Karhu, T.; Mäkelä, J.; Herzig, K.-H.; Karttunen, T.J.; Mäkinen, M.J. Preoperative anemia in colorectal cancer: Relationships with tumor characteristics, systemic inflammation, and survival. Sci. Rep. 2018, 8, 1126. [Google Scholar] [CrossRef]
  27. Väyrynen, J.P.; Vornanen, J.; Tervahartiala, T.; Sorsa, T.; Bloigu, R.; Salo, T.; Tuomisto, A.; Mäkinen, M.J. Serum MMP-8 Levels increase in colorectal cancer and correlate with disease course and inflammatory properties of primary tumors. Int. J. Cancer 2012, 131, E463–E474. [Google Scholar] [CrossRef]
  28. Malietzis, G.; Giacometti, M.; Askari, A.; Nachiappan, S.; Kennedy, R.H.; Faiz, O.D.; Aziz, O.; Jenkins, J.T. A preoperative neutrophil to lymphocyte ratio of 3 predicts disease-free survival after curative elective colorectal cancer surgery. Ann. Surg. 2014, 260, 287–292. [Google Scholar] [CrossRef]
  29. Tuppurainen, K.; Mäkinen, J.M.; Junttila, O.; Liakka, A.; Kyllönen, A.P.; Tuominen, H.; Karttunen, T.J.; Mäkinen, M.J. Morphology and microsatellite instability in sporadic serrated and non-serrated colorectal cancer. J. Pathol. 2005, 207, 285–294. [Google Scholar] [CrossRef]
  30. Bosman, F.T.; Carneiro, F.; Hruban, R.H.; Theise, N.D. (Eds.) WHO Classification of Tumours of the Digestive System, 4th ed.; International Agency for Research on Cancer: Lyon, France, 2010; Volume 3. [Google Scholar]
  31. Sajanti, S.A.; Sirniö, P.; Väyrynen, J.P.; Tuomisto, A.; Klintrup, K.; Mäkelä, J.; Ristimäki, A.; Mäkinen, M.J. VE1 Immunohistochemistry accurately detects BRAF V600E mutations in colorectal carcinoma and can be utilized in the detection of poorly differentiated colorectal serrated adenocarcinoma. Virchows Arch. 2014, 464, 637–643. [Google Scholar] [CrossRef] [PubMed]
  32. Martin, L.; Birdsell, L.; Macdonald, N.; Reiman, T.; Clandinin, M.T.; McCargar, L.J.; Murphy, R.; Ghosh, S.; Sawyer, M.B.; Baracos, V.E. Cancer cachexia in the age of obesity: Skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J. Clin. Oncol. 2013, 31, 1539–1547. [Google Scholar] [CrossRef]
  33. Hopkins, J.J.; Reif, R.L.; Bigam, D.L.; Baracos, V.E.; Eurich, D.T.; Sawyer, M.B. The impact of muscle and adipose tissue on long-term survival in patients with stage I to III colorectal cancer. Dis. Colon Rectum 2019, 62, 549–560. [Google Scholar] [CrossRef] [PubMed]
  34. Chen, W.-Z.; Chen, X.-D.; Ma, L.-L.; Zhang, F.-M.; Lin, J.; Zhuang, C.-L.; Yu, Z.; Chen, X.-L.; Chen, X.-X. Impact of visceral obesity and sarcopenia on short-term outcomes after colorectal cancer surgery. Dig. Dis. Sci. 2018, 63, 1620–1630. [Google Scholar] [CrossRef]
  35. Choi, M.H.; Oh, S.N.; Lee, I.K.; Oh, S.T.; Won, D.D. Sarcopenia is negatively associated with long-term outcomes in locally advanced rectal cancer. J. Cachexia Sarcopenia Muscle 2018, 9, 53–59. [Google Scholar] [CrossRef]
  36. Huang, D.-D.; Wang, S.-L.; Zhuang, C.-L.; Zheng, B.-S.; Lu, J.-X.; Chen, F.-F.; Zhou, C.-J.; Shen, X.; Yu, Z. Sarcopenia, as defined by low muscle mass, strength and physical performance, predicts complications after surgery for colorectal cancer. Colorectal Dis. 2015, 17, O256–O264. [Google Scholar] [CrossRef]
  37. Xiao, J.; Caan, B.J.; Cespedes Feliciano, E.M.; Meyerhardt, J.A.; Kroenke, C.H.; Baracos, V.E.; Weltzien, E.; Kwan, M.L.; Alexeeff, S.E.; Castillo, A.L.; et al. the association of medical and demographic characteristics with sarcopenia and low muscle radiodensity in patients with nonmetastatic colorectal cancer. Am. J. Clin. Nutr. 2019, 109, 615–625. [Google Scholar] [CrossRef] [PubMed]
  38. Abbass, T.; Dolan, R.D.; Laird, B.J.; McMillan, D.C. The relationship between imaging-based body composition analysis and the systemic inflammatory response in patients with cancer: A systematic review. Cancers 2019, 11, 1304. [Google Scholar] [CrossRef] [Green Version]
  39. Boonpipattanapong, T.; Chewatanakornkul, S. Preoperative carcinoembryonic antigen and albumin in predicting survival in patients with colon and rectal carcinomas. J. Clin. Gastroenterol. 2006, 40, 592–595. [Google Scholar] [CrossRef]
  40. Guthrie, G.J.K.; Charles, K.A.; Roxburgh, C.S.D.; Horgan, P.G.; McMillan, D.C.; Clarke, S.J. The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer. Crit. Rev. Oncol. Hematol. 2013, 88, 218–230. [Google Scholar] [CrossRef] [PubMed]
  41. Gabay, C.; Kushner, I. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 1999, 340, 448–454. [Google Scholar] [CrossRef] [PubMed]
  42. Nagareddy, P.R.; Murphy, A.J.; Stirzaker, R.A.; Hu, Y.; Yu, S.; Miller, R.G.; Ramkhelawon, B.; Distel, E.; Westerterp, M.; Huang, L.-S.; et al. Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab. 2013, 17, 695–708. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Guo, X.; Zhang, S.; Zhang, Q.; Liu, L.; Wu, H.; Du, H.; Shi, H.; Wang, C.; Xia, Y.; Liu, X.; et al. Neutrophil:Lymphocyte ratio is positively related to type 2 diabetes in a large-scale adult population: A Tianjin chronic low-grade systemic inflammation and health cohort study. Eur. J. Endocrinol. 2015, 173, 217–225. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Mertoglu, C.; Gunay, M. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as useful predictive markers of prediabetes and diabetes mellitus. Diabetes Metab. Syndr. 2017, 11 (Suppl. 1), S127–S131. [Google Scholar] [CrossRef] [PubMed]
  45. Dhillon, R.J.S.; Hasni, S. Pathogenesis and Management of Sarcopenia. Clin. Geriatr. Med. 2017, 33, 17–26. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Mäkinen, M.J. Colorectal serrated adenocarcinoma. Histopathology 2007, 50, 131–150. [Google Scholar] [CrossRef] [PubMed]
  47. Mukhopadhyay, S.; Vander Heiden, M.G.; McCormick, F. The metabolic landscape of RAS-driven cancers from biology to therapy. Nat. Cancer 2021, 2, 271–283. [Google Scholar] [CrossRef] [PubMed]
  48. He, P.; Zou, Y.; Qiu, J.; Yang, T.; Peng, L.; Zhang, X. Pretreatment 18F-FDG PET/CT imaging predicts the KRAS/NRAS/BRAF gene mutational status in colorectal cancer. J. Oncol. 2021, 2021, 6687291. [Google Scholar] [CrossRef]
  49. Shirdel, M.; Andersson, F.; Myte, R.; Axelsson, J.; Rutegård, M.; Blomqvist, L.; Riklund, K.; van Guelpen, B.; Palmqvist, R.; Gylling, B. Body composition measured by computed tomography is associated with colorectal cancer survival, also in early-stage disease. Acta Oncol. 2020, 59, 799–808. [Google Scholar] [CrossRef]
  50. Mäkinen, M.J.; George, S.M.; Jernvall, P.; Mäkelä, J.; Vihko, P.; Karttunen, T.J. colorectal carcinoma associated with serrated adenoma--prevalence, histological features, and prognosis. J. Pathol. 2001, 193, 286–294. [Google Scholar] [CrossRef]
  51. Cespedes Feliciano, E.M.; Kroenke, C.H.; Meyerhardt, J.A.; Prado, C.M.; Bradshaw, P.T.; Kwan, M.L.; Xiao, J.; Alexeeff, S.; Corley, D.; Weltzien, E.; et al. Association of systemic inflammation and sarcopenia with survival in nonmetastatic colorectal cancer. JAMA Oncol. 2017, 3, e172319. [Google Scholar] [CrossRef]
  52. Aleixo, G.F.P.; Shachar, S.S.; Nyrop, K.A.; Muss, H.B.; Malpica, L.; Williams, G.R. Myosteatosis and prognosis in cancer: Systematic review and meta-analysis. Crit. Rev. Oncol. Hematol. 2020, 145, 102839. [Google Scholar] [CrossRef] [PubMed]
  53. Kroenke, C.H.; Prado, C.M.; Meyerhardt, J.A.; Weltzien, E.K.; Xiao, J.; Cespedes Feliciano, E.M.; Caan, B.J. Muscle radiodensity and mortality in patients with colorectal cancer. Cancer 2018, 124, 3008–3015. [Google Scholar] [CrossRef] [PubMed]
  54. Miyamoto, Y.; Baba, Y.; Sakamoto, Y.; Ohuchi, M.; Tokunaga, R.; Kurashige, J.; Hiyoshi, Y.; Iwagami, S.; Yoshida, N.; Yoshida, M.; et al. Sarcopenia is a negative prognostic factor after curative resection of colorectal cancer. Ann. Surg. Oncol. 2015, 22, 2663–2668. [Google Scholar] [CrossRef] [PubMed]
  55. McShane, L.M.; Altman, D.G.; Sauerbrei, W.; Taube, S.E.; Gion, M.; Clark, G.M. Statistics subcommittee of the NCI-EORTC working group on cancer diagnostics REporting recommendations for tumour MARKer prognostic studies (REMARK). Br. J. Cancer 2005, 93, 387–391. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Jcm 11 02656 g001 550
Figure 1. (a) Diagram of body composition parameters in CRC patients. In total, 47 patients had coexisting sarcopenia and myosteatosis. (b) Diagram of systemic inflammation markers in CRC patients. Only 17 patients had both NLR > 3 and mGPS > 0.
Figure 1. (a) Diagram of body composition parameters in CRC patients. In total, 47 patients had coexisting sarcopenia and myosteatosis. (b) Diagram of systemic inflammation markers in CRC patients. Only 17 patients had both NLR > 3 and mGPS > 0.
Jcm 11 02656 g001
Jcm 11 02656 g002 550
Figure 2. Correlation network between sarcopenia, myosteatosis, serum cytokines, CRP, Hb, and albumin established by the Cytoscape software platform utilizing the Perfuse force-directed algorithm. Variables are presented by nodes and their associations by edges. Correlations with p < 0.1 are shown and the edge length illustrates the significance of the association. The green edge illustrates a positive correlation between myosteatosis and NLR, and red edges negative correlations between sarcopenia/myosteatosis and other variables.
Figure 2. Correlation network between sarcopenia, myosteatosis, serum cytokines, CRP, Hb, and albumin established by the Cytoscape software platform utilizing the Perfuse force-directed algorithm. Variables are presented by nodes and their associations by edges. Correlations with p < 0.1 are shown and the edge length illustrates the significance of the association. The green edge illustrates a positive correlation between myosteatosis and NLR, and red edges negative correlations between sarcopenia/myosteatosis and other variables.
Jcm 11 02656 g002
Jcm 11 02656 g003 550
Figure 3. Kaplan–Meier survival curves for (A) the presence of myosteatosis and overall survival, (B) the presence of myosteatosis and sarcopenia and disease-free survival, (C) the presence of myosteatosis and sarcopenia and overall survival, and (D) the presence of myosteatosis and sarcopenia and cancer-specific survival.
Figure 3. Kaplan–Meier survival curves for (A) the presence of myosteatosis and overall survival, (B) the presence of myosteatosis and sarcopenia and disease-free survival, (C) the presence of myosteatosis and sarcopenia and overall survival, and (D) the presence of myosteatosis and sarcopenia and cancer-specific survival.
Jcm 11 02656 g003
Table
Table 1. Characteristics of colorectal cancer patients.
Table 1. Characteristics of colorectal cancer patients.
Colorectal Cancer Patients (n = 222)n (%)
Body composition
Normal muscle79 (35.6%)
Myosteatosis alone20 (9.0%)
Sarcopenia alone76 (34.2%)
Both myosteatosis and sarcopenia47 (21.2%)
Age
<70 years old95 (42.8%)
≥70 years old127 (57.2%)
Gender
Male117 (52.7%)
Female105 (47.3%)
BMI categories
Underweight < 18.5 kg/m23 (1.4%)
Normal weight 18.5–24.9 kg/m273 (32.9%)
Overweight 25–29.9 kg/m292 (41.4%)
Obese ≥ 30 kg/m254 (24.3%)
Tumor location
Proximal colon89 (40.1%)
Distal colon58 (26.1%)
Rectum75 (33.8%)
TNM stage
Stage I42 (18.9%)
Stage II75 (33.8%)
Stage III73 (32.9%)
Stage IV32 (14.4%)
Depth of invasion
T113 (5.9%)
T243 (19.4%)
T3152 (68.5%)
T414 (6.3%)
Nodal metastases
N0120 (54.1%)
N167 (30.2%)
N235 (15.8%)
Distant metastases
M0190 (85.6%)
M132 (14.4%)
Morphology
conventional156 (70.3%)
serrated66 (29.7%)
Operation type
Curative192 (86.5%)
Palliative30 (13.5%)
ASA classification
1 (no systemic diseases)13 (5.9%)
2 (mild systemic disease)96 (43.2%)
3 (severe systemic disease)84 (37.8%)
4 (very severe systemic disease)18 (8.1%)
Coronary artery disease
No177 (79.7%)
Yes45 (20.3%)
Diabetes
No185 (83.3%)
Yes37 (16.7%)
Preoperative blood samples
Hemoglobin, g/L125.7 (±17.0) [86–167]
CEA, μg/L32.3 (±188.8) [0.5–2423.0]
Albumin, g/L42.7 (±4.4) [21–69]
C-reactive protein, mg/L10.4 (±25.3) [0.0–189.0]
NLR
≤3165 (75%)
>355 (25%)
Modified Glasgow prognostic score
0177 (79.7%)
141 (18.5%)
24 (1.8%)
5-year cancer recurrence43 (19.4%)
Died in 90 days8 (3.6%)
Died in 5 years75 (33.8%)
Follow-up, month82 (± 45.3) [0.10–164.5]
ASA: American Society of Anesthesiologists; BMI: body mass index; CEA: carcinoembryonic antigen; NLR: neutrophil–lymphocyte ratio.
Table
Table 2. Distribution of clinocopathological factors in myosteatosis and sarcopenia patient groups.
Table 2. Distribution of clinocopathological factors in myosteatosis and sarcopenia patient groups.
FactorsNeither Sarcopenia
Nor Myosteatosis
(n = 79)		Sarcopenia Only,
No Myosteatosis
(n = 76)		Myosteatosis Only,
No Sarcopenia
(n = 20)		Both Sarcopenia and
Myosteatosis
(n = 47)		p-Value
Age, mean, years, (±SD)65 (±11.2)70 (±11.0)72 (±9.9)76 (±9.7)<0.001
Age
≤70 years (n = 95)51 (64.6%)27 (35.5%)6 (30.0%)11 (23.4%)<0.001
>70 years (n = 127)28 (35.4%)49 (64.5%)14 (70.0%)36 (76.6%)
Gender
Male (n = 117)48 (60.8%)40 (52.6%)8 (40.0%)21 (44.7%)0.211
Female (n = 105)31 (39.2%)36 (47.4%)12 (60.0%)26 (55.3%)
BMI, kg/m2
<18.5 (n = 3)1 (1.3%)2 (2.6%)0 (0.0%)0 (0.0%)<0.001
18.5–24.9 (n = 73)27 (34.2%)15 (19.7%)6 (30.0%)25 (53.2%)
25–29.9 (n = 92)24 (30.4%)47 (61.8%)7 (35.0%)14 (29.8%)
>30 (n = 54)27 (34.2%)12 (15.8%)7 (35.0%)8 (17.0%)
Tumor location
Proximal colon (n = 89)28 (35.4%)24 (31.6%)11 (55.0%)26 (55.3%)0.039
Distal colon (n = 58)17 (21.5%)26 (34.2%)5 (25.0%)10 (21.3%)
Rectum (n = 75)34 (43.0%)26 (34.2%)4 (20.0%)11 (23.4%)
WHO grade
Grade 1 (n = 56)20 (25.3%)16 (21.1%)6 (30.0%)14 (29.8%)0.176
Grade 2 (n = 140)53 (67.1%)49 (64.5%)14 (70.0%)24 (51.1%)
Grade 3 (n = 26)6 (7.6%)11 (14.5%)0 (0.0%)9 (19.1%)
TNM stage
I (n = 42)18 (22.8%)8 (10.5%)5 (25.0%)11 (23.4%)0.398
II (n = 75)27 (34.2%)27 (35.5%)5 (25.0%)16 (34.0%)
III (n = 73)24 (30.4%)31 (40.8%)5 (25.0%)13 (27.7%)
IV (n = 32)10 (12.7%)10 (13.2%)5 (25.0%)7 (14.9%)
Depth of invasion
T1 (n = 13)7 (8.9%)3 (3,9%)1 (5.0%)2 (4.3%)0.193
T2 (n = 43)16 (20.3%)9 (11.8%)6 (30.0%)12 (25.5%)
T3 (n = 152)50 (63.3%)61 (80.3%)13 (65.0%)28 (59.6%)
T4 (n = 14)6 (7.6%)3 (3.9%)0 (0.0%)5 (10.6%)
Nodal metastases
N0 (n = 120)46 (58.2%)36 (47.4%)10 (50.0%)28 (59.6%)0.382
N1 (n = 67)19 (24.1%)30 (39.5%)5 (25.0%)13 (27.7%)
N2 (n = 35)14 (17.7%)10 (13.2%)5 (25.0%)6 (12.8%)
Distant metastases
M0 (n = 190)69 (87.3%)66 (86.8%)15 (75.0%)40 (85.1%)0.541
M1 (n = 32)10 (12.7%)10 (13.2%)5 (25.0%)7 (14.9%)
Serrated morphology
yes (n = 66)18 (22.8%)15 (19.7%)9 (45.0%)24 (51.1%)<0.001
no (n = 156)61 (77.2%)61 (80.3%)11 (55.0%)23 (48.9%)
ASA grade
I (n = 13)7 (9.1%)4 (5.4%)1 (5.6%)1 (2.4%)0.004
II (n = 96)46 (59.7%)34 (45.9%)4 (22.2%)12 (28.6%)
III (n = 84)18 (23.4%)31 (41.9%)11 (61.1%)24 (57.1%)
IV (n = 18)6 (7.8%)5 (6.8%)2 (11.1%)5 (11.9%)
Diabetes
No (n = 185)66 (83.5%)67 (88.2%)15 (75.0%)37 (78.7%)0.354
Yes (n = 37)13 (16.6%)9 (11.8%)5 (25.0%)10 (21.3%)
Coronary artery disease
No (n = 177)67 (84.8%)62 (81.6%)13 (65.0%)35 (74.5%)0.177
Yes (n = 45)12 (15.2%)14 (18.4%)7 (35.0%)12 (25.5%)
Use of blood pressure lowering medication
No (n = 95)43 (54.4%)31 (40.3%)6 (30.0%)15 (31.9%)0.043
Yes (n = 127)36 (45.6%)45 (59.2%)14 (70.0%)32 (68.1%)
Use of cholesterol lowering medication
No (n = 146)54 (68.4%)46 (60.5%)11 (55.0%)35 (74.5%)0.290
Yes (n = 76)25 (31.6%)30 (39.5%)9 (45.0%)12 (25.5%)
CRP, mg/L
≤10 (n = 176)63 (79.7%)60 (78.9%)18 (90.0%)35 (74.5%)0.584
>10 (n = 46)16 (20.3%)16 (21.1%)2 (10.0%)12 (25.5%)
Modified Glasgow prognostic score
0 (n = 177)63 (79.7%)61 (80.3%)18 (90.0%)35 (74.5%)0.331
1 (n = 41)16 (20.3%)14 (18.4%)2 (11.8%)9 (19.1%)
2 (n = 4)0 (0.0%)1 (1.3%)0 (0.0%)3 (6.4%)
NLR
≤3 (n = 165)68 (87.2%)53 (70.7%)16 (76.5%)28 (59.6%)0.005
>3 (n = 55)10 (12.8%)22 (29.3%)4 (23.5%)19 (40.4%)
Albumin, g/L
≤35 (n = 9) 0 (0.0%)3 (3.9%)1 (5.0%)5 (10.6%)0.018
>35 (n = 213)79 (100.0%)73 (96.1%)19 (95.0%)42 (89.4%)
BRAF VE1
immunohistochemistry
Negative (n = 196)72 (91.1%)70 (92.1%)16 (80.0%)38 (80.9%)0.126
Positive (n = 26)7 (8.9%)6 (7.9%)4 (20.0%)9 (19.1%)
ASA: American Society of Anesthesiologists; BMI: body mass index; CRP: C-reactive protein; NLR: neutrophil–lymphocyte Ratio.
Table
Table 3. Serum cytokine and chemokine levels, blood cell counts, and other laboratory parameters in relation to sarcopenia and myosteatosis.
Table 3. Serum cytokine and chemokine levels, blood cell counts, and other laboratory parameters in relation to sarcopenia and myosteatosis.
FactorsNeither
Sarcopenia Nor Myosteatosis 1 		Sarcopenia Only,
No Myosteatosis 2		Myosteatosis Only,
No Sarcopenia 3		Both
Sarcopenia and Myosteatosis 4		p-Value
Laboratory parameters, median (IQR) datadata
Serum CRP, mg/L2.24 (0.70–8.17)2.00 (0.71–7.00)2.80 (0.91–7.00)4.00 (1.00–11.81)0.536
Serum Albumin, g/L43.00 (41.0–45.0)43.0 (41.0–45.0)43.0 (39.3–44.8)42.0 (38.0–45.0)0.264
Blood leukocytes 56.70 (5.60–7.90)6.65 (5.60–7.98)7.60 (6.48–8.70)7.00 (5.80–8.80)0.197
Blood neutrophils 53.80 (2.88–4.99)4.00 (2.90–5.00)4.70 (3.93–5.80)4.40 (3.30–5.50)0.102
Blood lymphocytes 51.90 (1.50–2.33)1.80 (1.30–2.10)1.95 (1.63–2.58)1.70 (1.20–2.30)0.133
Blood NLR2.08 (1.47–2.62)2.22 (1.60–3.26)2.09 (1.64–2.83)2.67 (1.71–3.43)0.017
Blood monocytes 50.60 (0.46–0.70)0.60 (0.40–0.74)0.70 (0.53–0.80)0.70 (0.50–0.80)0.024
Hemoglobin, g/L130 (118–142)128 (110–139)123 (111–140)120 (109–129)0.011
CEA, μg/L1.60 (1.00–3.98)1.80 (1.10–7.90)2.85 (1.00–20.68)2.70 (1.40–6.73)0.104
Cytokines, pg/mL, median (IQR)
IL-1R180.8 (50.8)61.9 (58.8)46.6 (68.7)50.7 (83.5)0.664
IL-41.00 (0.37)0.86 (0.50)0.78 (0.28)0.87 (0.41)0.336
IL-66.47 (5.96)4.50 (4.51)4.58 (3.46)4.69 (10.20)0.474
IL-76.24 (3.35)5.34 (3.61)5.01 (2.24)4.84 (4.00)0.577
CXCL813.4 (6.90)10.9 (8.03)11.5 (3.39)11.3 (10.34)0.713
IL-99.62 (7.27)7.57 (10.70)6.88 (10.13)5.65 (8.04)0.106
IL-1230.4 (25.6)31.6 (24.1)31.7 (24.2)27.9 (30.5)0.684
IFNg37.7 (17.4)30.8 (22.9)25.3 (16.9)27.3 (20.6)0.104
CXCL10858 (489)924 (539)1068 (1055)973 (738)0.763
CCL214.6 (9.3)15.4 (20.5)17.5 (11.3)14.7 (17.1)0.639
CCL464.5 (35.7)59.4 (18.6)58.6 (59.1)69.0 (39.8)0.550
CCL11138 (67.6)123 (83.8)155 (96.7)114 (77.7)0.492
PDGF-BB9280 (4823)8412 (5360)8935 (7759)8577 (10810)0.986
CRP: C-reactive protein; NLR: neutrophil–lymphocyte ratio; CEA: carcinoembryonic antigen; 1: N = 79 in laboratory parameters, N = 30 in cytokine measurements; 2: N = 36 in laboratory parameters, N = 36 in cytokine measurements; 3: N = 20 in laboratory parameters, N = 7 in cytokine measurements; 4: N = 47 in laboratory parameters, N = 16 in cytokine measurements; 5: ×109/L.
Table
Table 4. Multivariable binary regression model for myosteatosis probability.
Table 4. Multivariable binary regression model for myosteatosis probability.
FactorsOR95% CIp-Value
Age (<70 vs. ≥70 years)1.920.87–4.230.105
Tumor location (proximal vs. distal colon)0.5830.24–1.400.231
Tumor location (proximal colon vs. rectum)0.610.27–1.360.228
Serrated morphology (yes vs. no)3.761.82–7.76<0.001
ASA grade (I–II vs. III–IV)2.661.20–5.930.017
NLR (<3 vs. >3)1.390.64–2.960.407
Albumin level (<35 g/L vs. >35 g/L)0.320.07–1.510.153
Blood pressure lowering medication (yes/no)1.150.53–2.500.730
Abbreviations: OR: odds ratio; CI: confidence interval; ASA: American Society of Anesthesiologists; NLR: neutrophil–lymphocyte ratio.
Table
Table 5. Multivariable binary regression model for sarcopenia probability.
Table 5. Multivariable binary regression model for sarcopenia probability.
FactorsOR95% CIp-Value
Age (<70 vs. ≥70 years)3.231.65–6.31<0.001
Tumor location (proximal vs. distal colon)1.780.80–3.950.157
Tumor location (proximal colon vs. rectum)1.120.55–2.280.751
Serrated morphology (yes vs. no)1.130.58–2.210.723
ASA grade (I–II vs. III–IV)1.070.52–2.190.860
NLR (<3 vs. >3)2.341.13–4.840.022
Albumin level (<35 g/L vs. >35 g/L)0.220.03–2.020.181
Blood pressure lowering medication (yes/no)0.840.43–1.650.612
Abbreviations: OR: odds ratio; CI: confidence interval; ASA: American Society of Anesthesiologists; NLR: neutrophil–lymphocyte ratio.
Table
Table 6. Multivariable Cox regression model for overall survival.
Table 6. Multivariable Cox regression model for overall survival.
FactorsHR95% CIp-Value
Age (<70 vs. ≥70)2.691.58–4.60<0.001
Tumor invasion (T1–T2 vs. T3–T4)1.220.68–2.190.497
Nodal metastases (N0 vs. N1–N2)2.741.60–4.68<0.001
Distant metastases (M0 vs. M1)5.543.19–9.62<0.001
Myosteatosis (No vs. Yes)1.550.96–2.500.075
Abbreviations: HR: hazard ratio; CI: confidence interval. Median follow-up time 60 months; 75 (33.8%) events.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Aro, R.; Meriläinen, S.; Sirniö, P.; Väyrynen, J.P.; Pohjanen, V.-M.; Herzig, K.-H.; Rautio, T.T.; Mäkäräinen, E.; Häivälä, R.; Klintrup, K.; et al. Sarcopenia and Myosteatosis Are Associated with Neutrophil to Lymphocyte Ratio but Not Glasgow Prognostic Score in Colorectal Cancer Patients. J. Clin. Med. 2022, 11, 2656. https://0-doi-org.brum.beds.ac.uk/10.3390/jcm11092656

AMA Style

Aro R, Meriläinen S, Sirniö P, Väyrynen JP, Pohjanen V-M, Herzig K-H, Rautio TT, Mäkäräinen E, Häivälä R, Klintrup K, et al. Sarcopenia and Myosteatosis Are Associated with Neutrophil to Lymphocyte Ratio but Not Glasgow Prognostic Score in Colorectal Cancer Patients. Journal of Clinical Medicine. 2022; 11(9):2656. https://0-doi-org.brum.beds.ac.uk/10.3390/jcm11092656

Chicago/Turabian Style

Aro, Raila, Sanna Meriläinen, Päivi Sirniö, Juha P. Väyrynen, Vesa-Matti Pohjanen, Karl-Heinz Herzig, Tero T. Rautio, Elisa Mäkäräinen, Reetta Häivälä, Kai Klintrup, and et al. 2022. "Sarcopenia and Myosteatosis Are Associated with Neutrophil to Lymphocyte Ratio but Not Glasgow Prognostic Score in Colorectal Cancer Patients" Journal of Clinical Medicine 11, no. 9: 2656. https://0-doi-org.brum.beds.ac.uk/10.3390/jcm11092656

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop